Evidence map›Paper›PMID 35179714›Full record

ArticleOphthalmology and therapy2022

Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry.

Sanjeeb Bhandari, Pierre-Henry Gabrielle, Vuong Nguyen, Vincent Daien, Francesco Viola, Walid Bougamha, Stephanie Young, Barbara Romero-Nuñez, Marc Figueras-Roca, Javier Zarranz-Ventura and 4 more

Open access · goldAbstract read
In one paragraph

Article in Ophthalmology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 5 countries.

Sanjeeb BhandariSave Sight Institute, Discipline of Ophthalmology and Eye Health, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia. sbha5189@uni.sydney.edu.au.ORCID http://orcid.org/0000-0002-4110-4274
Pierre-Henry GabrielleSave Sight Institute, Discipline of Ophthalmology and Eye Health, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Vuong NguyenSave Sight Institute, Discipline of Ophthalmology and Eye Health, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Vincent DaienSave Sight Institute, Discipline of Ophthalmology and Eye Health, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Francesco ViolaFondazione Cà Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Walid BougamhaDepartment of Ophthalmology, University Hospital Nice, University of Nice, Nice, France.
Stephanie YoungGladesville Eye Specialists, Gladesville, NSW, Australia.
Barbara Romero-NuñezInstitut Clínic d'Oftalmología (ICOF), Hospital Clinic of Barcelona, Barcelona, Spain.
Marc Figueras-RocaInstitut Clínic d'Oftalmología (ICOF), Hospital Clinic of Barcelona, Barcelona, Spain.
Javier Zarranz-VenturaInstitut Clínic d'Oftalmología (ICOF), Hospital Clinic of Barcelona, Barcelona, Spain.
Daniel BarthelmesSave Sight Institute, Discipline of Ophthalmology and Eye Health, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Laura SararolsFundació Privada Hospital Asil Granollers, Granollers, Spain.
Mark GilliesSave Sight Institute, Discipline of Ophthalmology and Eye Health, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Catherine Creuzot-GarcherDepartment of Ophthalmology, Dijon University Hospital, Dijon, France.
The University of Sydney · AUHospital Clínic de Barcelona · ESHospital General de Granollers · ESMaison des Sciences sociales et des Humanités de Dijon · FRMotor Neurone Disease Research Australia · AUUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPhase III clinical trials of dexamethasone intravitreal implant for diabetic macular oedema (DMO) have reported significant improvements in visual acuity (VA). Studies evaluating the treatment of DMO in routine clinical practice provide data to identify areas that need improvement. This study evaluated 12-month treatment outcomes of dexamethasone implant for DMO in routine clinical practice.

methodsRetrospective data analysis of eyes that started dexamethasone implant for DMO from 1 June 2013 to 30 April 2019 in routine clinical practice tracked in the Fight Retinal Blindness! Registry.

resultsOf the 4282 eyes (2518 patients) that started DMO treatment in the specified period, 267 (6%) eyes (204 patients) received 454 dexamethasone implant injections. Two-fifths (106 eyes) had received prior treatment for DMO. The mean (95% confidence interval [CI]) VA change at 12 months was 1.8 (- 0.5, 4.2) letters from the mean (standard deviation [SD]) VA of 56.5 (19.8) letters at baseline, with 41% eyes achieving at least 20/40. The mean (95% CI) change in central subfield thickness over 1 year was - 79 (- 104, - 54) µm from a mean (SD) of 459 (120) µm at baseline. Eyes that completed 1 year of follow-up received a median (Q1, Q3) of 2 (1, 2) dexamethasone implants. One-tenth of phakic eyes received cataract surgery while 2% had a pressure response requiring anti-glaucoma medications.

conclusionsOne-year treatment outcomes of dexamethasone intravitreal implant for DMO in routine clinical practice were inferior to those in the clinical trials perhaps because of fewer treatments in clinical practice.

Indexed as

DexamethasoneDiabetic macular oedemaReal-world outcomesRoutine clinical practice

Identifiers

PMID35179714
PMCPMC8927495
OpenAlexW4213126062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.